Latest filing published 09 Feb 2024 for Evolus, Inc..
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 4 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -10.3%Entry US$10.53 · Close at T+365 US$9.45
- -10.9%Entry US$10.72 · Close at T+365 US$9.55
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Robert Hayman: trading record in brief
Robert Hayman, listed as board member, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Evolus, Inc. and American Medical Technologies Inc/de. Between 23 July 2006 and 7 February 2024, the trades on record add up to 17 filings.
Every open-market trade on record is a purchase: 11 purchases worth €219k, and no sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 4 share grants.
The median purchase comes to €3,127. On 4 out of 4 purchases, another insider of the same company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. Looking at 4 purchases old enough to measure, the stock rose over the following 90 days in 0% of cases; the median change was -29.9%. Past outcomes like these are no guarantee of what comes next.
On 9 February 2024 came the latest disclosure, a share grant in Evolus, Inc. The last purchase on record was published on 13 September 2022, which is 1,518 days ago. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Robert Hayman
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 6,464 shares0Common StockSEC:0001570562-24-000022:0
- 366 shares0Common StockSEC:0001570562-23-000090:1
- 218 shares0Common StockSEC:0001570562-23-000090:0
- 8,293 shares0Common StockSEC:0001570562-23-000025:0
- 1,091 shares@ US$10.785.7% of flowCommon StockSEC:0001570562-22-000136:1Canonical exit: 11 Dec 2022 (T+90)
- 5,000 shares@ US$10.0526.1% of flowCommon StockSEC:0001570562-22-000135:0Canonical exit: 6 Dec 2022 (T+90)
- 8,909 shares@ US$10.347147.9% of flowCommon StockSEC:0001570562-22-000136:0Canonical exit: 8 Dec 2022 (T+90)
- 4,967 shares@ US$10.0526.0% of flowCommon StockSEC:0001570562-22-000132:0Canonical exit: 6 Dec 2022 (T+90)
- 15,568 shares0Common StockSEC:0001570562-22-000047:0
- 19,313 shares0Common StockSEC:0001570562-21-000038:0
- 10,000 shares@ US$0.23Common StockSEC:0000898080-06-000375:0Canonical exit: 19 Dec 2006 (T+90)
- 15,000 shares@ US$0.25Common StockSEC:0000898080-06-000375:1Canonical exit: 19 Dec 2006 (T+90)
- 5,475 shares@ US$0.25Common StockSEC:0000898080-06-000358:0Canonical exit: 16 Nov 2006 (T+90)
- 20,000 shares@ US$0.23Common StockSEC:0000898080-06-000356:0Canonical exit: 2 Nov 2006 (T+90)
- 16,000 shares@ US$0.25Common StockSEC:0000898080-06-000356:1Canonical exit: 12 Nov 2006 (T+90)
- 100 shares@ US$0.23Common StockSEC:0000898080-06-000328:0Canonical exit: 21 Oct 2006 (T+90)
- 12,500 shares@ US$0.25Common StockSEC:0000898080-06-000328:1Canonical exit: 25 Oct 2006 (T+90)
17 of 17 declarations
